
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
The company’s most anticipated product, Stemchymal®, an allogeneic adipose-derived mesenchymal stem cell (MSC) therapy, has completed Phase 2 clinical trials in Taiwan and Japan for spinocerebellar ataxia (SCA) and has received orphan drug designation in …